Gavin Andrews
GlaxoSmithKline
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Gavin Andrews.
Biomacromolecules | 2008
David Jones; Brendan C.O. Muldoon; A. David Woolfson; Gavin Andrews; F.Dominic Sanderson
This study describes the formulation and physicochemical characterization of poly(acrylic acid) (PAA) organogels, designed as bioactive implants for improved treatment of infectious diseases of the oral cavity. Organogels were formulated containing a range of concentrations of PAA (3-10% w/w) and metronidazole (2 or 5% w/w, representing a model antimicrobial agent) in different nonaqueous solvents, namely, glycerol (Gly), polyethylene glycol (PEG 400), or propylene glycol (PG). Characterization of the organogels was performed using flow rheometry, compressional analysis, oscillatory rheometry, in vitro mucoadhesion, moisture uptake, and drug release, methods that provide information pertaining to the nonclinical and clinical use of these systems. Increasing the concentration of PAA significantly increased the consistency, compressibility, storage modulus, loss modulus, dynamic viscosity, mucoadhesion, and the rate of drug release. These observations may be accredited to enhanced molecular polymer entanglement. In addition, the choice of solvent directly affected the physicochemical parameters of the organogels, with noticeable differences observed between the three solvents examined. These differences were accredited to the nature of the interaction of PAA with each solvent and, importantly, the density of the resultant physical cross-links. Good correlation was observed between the viscoelastic properties and drug release, with the exception of glycerol-based formulations containing 5 and 10% w/w PAA. This disparity was due to excessive swelling during the dissolution analysis. Ideally, formulations should exhibit controlled drug release, high viscoelasticity, and mucoadhesion, but should flow under minimal stresses. Based on these criteria, PEG 400-based organogels composed of 5% or 10% w/w PAA exhibited suitable physicochemical properties and are suggested to be a potentially interesting strategy for use as bioactive implants designed for use in the oral cavity.
Pharmaceutical Technology Europe | 2009
Gavin Andrews; David Jones; Daniel N. Margetson; M. McAllistar; Osama Abu Diak
European Journal of Parenteral & Pharmaceutical Sciences | 2010
Mathew Williams; David Jones; Yiwei Tian; Gavin Andrews
Archive | 2011
Gavin Andrews; David Jones; Sean Gorman
Modern Mucosal Vaccines, Adjuvants and Microbicides | 2010
Rhonda Curran; Louise Donnelly; Ryan Morrow; C. Fraser; John S. Tregoning; Gavin Andrews; Karl Malcolm; David Woolfson; Robin J. Shattock; Martin Cranage
Archive | 2009
Gavin Andrews; David Jones; Sean Gorman
Liposomes advances: progress in drug and vaccine delivery | 2009
Karl Malcolm; Prem N. Gupta; Rhonda Curran; Gavin Andrews
British Pharmaceutical Conference | 2009
Ryan Morrow; Louise Donnelly; Karl Malcolm; Rhonda Curran; Gavin Andrews; David Woolfson
5th Annual Grand Challenges in Global Health Meeting | 2009
Rhonda Curran; Louise Donnelly; Ryan Morrow; Gavin Andrews; Karl Malcolm; David Woolfson; Frank Wegmann; Quentin J. Sattentau; Martin Cranage; C. Fraser
5th Annual Grand Challenges in Global Health Meeting | 2009
Rhonda Curran; Louise Donnelly; Ryan Morrow; C. Fraser; Gavin Andrews; Martin Cranage; Karl Malcolm; David Woolfson; Robin J. Shattock